Prestige Consumer Healthcare (NYSE:PBH) Rating Lowered to Hold at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Several other brokerages also recently issued reports on PBH. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. Finally, DA Davidson reiterated a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $85.25.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock traded up $1.11 during trading hours on Thursday, hitting $78.31. 327,709 shares of the stock were exchanged, compared to its average volume of 294,271. Prestige Consumer Healthcare has a 12 month low of $58.22 and a 12 month high of $86.36. The business’s 50-day moving average is $80.56 and its two-hundred day moving average is $74.41. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock has a market capitalization of $3.87 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.08 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period last year, the firm posted $1.07 EPS. The business’s revenue was down .9% on a year-over-year basis. Equities research analysts expect that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PBH. Quest Partners LLC boosted its position in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC grew its stake in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank increased its holdings in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC raised its position in shares of Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after purchasing an additional 1,138 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.